Clinical Trials Directory

Trials / Unknown

UnknownNCT05531838

Prediabetes Management

A Community Controlled Study of MMC Mode Combined With CGM Therapeutic Monitoring Technology in the Management of Patients With Prediabetes

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
190 (estimated)
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
Sex
All
Age
20 Years – 79 Years
Healthy volunteers
Accepted

Summary

Systematically screen the high-risk population of diabetes in Xinqiao district to understand the characteristics of early glucose metabolism changes and pancreatic islet function changes in patients with pre diabetes. Relying on MMC platform and combined with CGM therapeutic monitoring technology to standardize the management of patients with prediabetes, it is expected that the annual conversion rate of diabetes in patients with prediabetes will be 8% (according to the literature, if the pre diabetes population is not intervened, the annual conversion rate of diabetes will be about 14%), which will move forward the management of diabetes and create a new mode of pre diabetes management.

Detailed description

Part I: Establish the first standardized study cohort of prediabetes patients in Songjiang On the basis of previous studies, we will continue to carry out early screening of diabetes high-risk groups. It is planned to complete 500 high-risk screening cases in Xinqiao area, and all screened patients will have their medical history and relevant laboratory examinations, and will be followed up regularly. The standard OGTT method was used for screening. The screening contents included: fasting blood glucose and insulin, blood glucose and insulin levels 2 hours after 75g glucose load, and glycosylated hemoglobin levels. In addition to glucose metabolism, other metabolic related diseases such as hematuria routine, liver and kidney function, uric acid, blood lipids, thyroid function, and urine protein / creatinine were also screened. The establishment of the high-quality high-risk screening project in Xinqiao community will establish the first standardized research cohort of diabetes high-risk and pre diabetes patients in Songjiang area, which has very important strategic significance. Part II: Standardized management and follow-up based on MMC mode combined with CGM therapeutic monitoring technology For patients with pre diabetes diagnosed by screening, we will rely on MMC mode and CGM technology for standardized management and follow-up. The management mode is mainly embodied in the following forms: ① using CGM Technology (dynamic glucose monitoring system for auxiliary Lishan instant sense hospital), on the basis of the original eating habits of patients, according to the guidelines and the training of MMC center, patients are guided to adjust their eating mode according to the glucose map monitored by the dynamic glucose monitoring system and the log recorded, so as to implement therapeutic monitoring, so as to control the blood glucose level within the target range as far as possible, And record the amount of various foods accordingly, and then maintain the eating mode and amount basically unchanged. ② Offline management. Patient education at least twice a year and hospital follow-up once a year; ③ Issue health instruction manuals, blood glucose monitoring diaries, etc; ④ A full-time wechat management group is established, and full-time intelligent assistants push diet, sports and other guidance every day. Taking the cases of diabetes patients screened in the previous study of the research group as the control, the annual conversion rate of diabetes was observed one year later.

Conditions

Interventions

TypeNameDescription
DEVICEFu Lishan instant sense hospital dynamic glucose monitoring systemUsing CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.

Timeline

Start date
2022-10-17
Primary completion
2023-10-30
Completion
2023-12-31
First posted
2022-09-08
Last updated
2022-09-08

Source: ClinicalTrials.gov record NCT05531838. Inclusion in this directory is not an endorsement.